Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2024-12-22
Based on 1111 first isolates · ED · Febrile UTI / pyelonephritis · 2023-12-24 → 2024-12-22
Emergency department
Per-organism detail: ED urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
ciprofloxacin 81 % (78 %–83 %)
Not covered: Enterococcus faecalis (8 %), Escherichia coli (4 %), Staphylococcus aureus (4 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
86 %
84 %
n = 82
nitrofurantoin NIT
trend · Escherichia coli not for this site
85 %
85 %
n = 82
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
82 %
80 %
n = 82
ciprofloxacin CIP
trend · Escherichia coli
81 %
77 %
n = 82
ceftriaxone CRO
trend · Escherichia coli
80 %
74 %
n = 82
mecillinam MEC
trend · Escherichia coli not for this site
80 %
79 %
n = 82
trimethoprim TMP
trend · Escherichia coli not for this site
76 %
72 %
n = 82
74 %
72 %
n = 82
51 %
49 %
n = 82
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
11 %
13 %
n = 82
4 %
4 %
n = 82
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
4 %
n = 82

Most likely organisms for this profile

Escherichia coli
56 %
Klebsiella pneumoniae
12 %
Enterococcus faecalis
8 %
Proteus mirabilis
7 %
Pseudomonas aeruginosa
4 %
Klebsiella oxytoca
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.